These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 14597479)

  • 1. Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione.
    Ebcioglu Z; Morgan J; Carey C; Capuzzi D
    Ann Intern Med; 2003 Nov; 139(9):W80. PubMed ID: 14597479
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.
    Senba H; Kawano M; Kawakami M
    J Atheroscler Thromb; 2006 Oct; 13(5):263-4. PubMed ID: 17146155
    [No Abstract]   [Full Text] [Related]  

  • 3. Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction.
    Schwing W; Hustak L; Taylor HC
    Endocr Pract; 2010; 16(3):382-8. PubMed ID: 20061291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.
    Ronsein GE; Reyes-Soffer G; He Y; Oda M; Ginsberg H; Heinecke JW
    Mol Cell Proteomics; 2016 Mar; 15(3):1083-93. PubMed ID: 26667175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.
    Linz PE; Lovato LC; Byington RP; O'Connor PJ; Leiter LA; Weiss D; Force RW; Crouse JR; Ismail-Beigi F; Simmons DL; Papademetriou V; Ginsberg HN; Elam MB
    Diabetes Care; 2014; 37(3):686-93. PubMed ID: 24296848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate.
    Venero CV; Thompson PD; Fernandez AB
    Am J Med; 2008 Oct; 121(10):e3-4. PubMed ID: 18823843
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.
    Ledl M; Hohenecker J; Francesconi C; Roots I; Bauer MF; Roden M
    Diabetologia; 2005 Oct; 48(10):1996-8. PubMed ID: 16132947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.
    Normén L; Frohlich J; Montaner J; Harris M; Elliott T; Bondy G
    Diabetes Care; 2004 Sep; 27(9):2241-2. PubMed ID: 15333491
    [No Abstract]   [Full Text] [Related]  

  • 9. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
    Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
    Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rhabdomyolysis induced by fenofibrate monotherapy].
    Archambeaud-Mouveroux F; Lopez S; Combes C; Lassandre S; Amaniou M; Teissier MP; Galinat S
    Rev Med Interne; 2006 Jul; 27(7):573-4. PubMed ID: 16716459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate.
    Ribas V; Palomer X; Roglans N; Rotllan N; Fievet C; Tailleux A; Julve J; Laguna JC; Blanco-Vaca F; Escolà-Gil JC
    Biochim Biophys Acta; 2005 Dec; 1737(2-3):130-7. PubMed ID: 16226489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
    Samineni D; Fichtenbaum CJ
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):995-1004. PubMed ID: 20604734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
    Farnier M; Ducobu J; Bryniarski L
    Curr Med Res Opin; 2011 Nov; 27(11):2165-73. PubMed ID: 21973199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study.
    Rull A; Geeraert B; Aragonès G; Beltrán-Debón R; Rodríguez-Gallego E; García-Heredia A; Pedro-Botet J; Joven J; Holvoet P; Camps J
    J Proteome Res; 2014 Mar; 13(3):1731-43. PubMed ID: 24479691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics.
    Leonard CE; Han X; Bilker WB; Flory JH; Brensinger CM; Flockhart DA; Gagne JJ; Cardillo S; Hennessy S
    Diabetes Res Clin Pract; 2016 May; 115():60-7. PubMed ID: 27242124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
    Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
    Farnier M; Steinmetz A; Retterstøl K; Császár A
    Clin Ther; 2011 Jan; 33(1):1-12. PubMed ID: 21397769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.
    Keidar S; Guttmann H; Stam T; Fishman I; Shapira C
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1192-4. PubMed ID: 17636555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.
    Samadfam R; Awori M; Bénardeau A; Bauss F; Sebokova E; Wright M; Smith SY
    J Endocrinol; 2012 Feb; 212(2):179-86. PubMed ID: 22062085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.